Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 5/20 | 0.57 |
| ▸ | JAK1 | P23458 | 2/20 | 0.51 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | PRKX | P51817 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24656050 | 0.79 | NUDT1 (0.59) | NUDT1JAK1EGLN2CHEK1MET | |
| SCHEMBL258972 | 0.79 | EGLN2 (0.50) | EGLN2CYP11B2PDE10AKDM4E | |
| SCHEMBL13465776 | 0.78 | NUDT1 (0.58) | NUDT1JAK1EGLN2CHEK1MET | |
| SCHEMBL45713 | 0.76 | NUDT1 (0.56) | NUDT1JAK1EGLN2CYP11B2PDE10A | |
| SCHEMBL27038245 | 0.76 | NUDT1 (0.56) | NUDT1JAK1EGLN2JAK3KDM4E | |
| SCHEMBL13218425 | 0.76 | CYP11B2 (0.45) | CYP11B2PDE10AKDM4E | |
| SCHEMBL30485242 | 0.76 | CYP11B2 (0.45) | CYP11B2PDE10A | |
| SCHEMBL13390440 | 0.76 | CYP11B2 (0.53) | CYP11B2PDE10A | |
| SCHEMBL30927826 | 0.76 | NUDT1 (0.56) | NUDT1JAK1EGLN2CHEK1MET | |
| SCHEMBL2773330 | 0.76 | NUDT1 (0.57) | NUDT1JAK1EGLN2CHEK1LTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118215664-B | Substituted triazoloheteroaryl compounds as USP1 inhibitors and uses thereof | 上海瑛派药业有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20240409538-A1 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4419522-A1 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2024-08-28 | — | — | EP | disclosed |
| CN-118215664-A | Substituted triazoloheteroaryl compounds as USP1 inhibitors and uses thereof | 上海瑛派药业有限公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2023066299-A1 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023066299-A1 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-04-27 | — | — | WO | disclosed |
| WO-2019149244-A1 | JAK INHIBITOR AND USE THEREOF | 南京明德新药研发股份有限公司 | 2019-08-08 | — | — | WO | disclosed |
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20150307520-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2015-10-29 | — | — | US | disclosed |
| US-20150291593-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LTD (CN) | 2015-10-15 | — | — | US | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307520-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | PIK3C3, PIK3C2B, PIK3C2A | NUDT1 2059/4885JAK1 54/4885EGLN2 1304/4885 |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | NUDT1 1120/4885JAK1 69/4885EGLN2 564/4885 |
| US-20240409538-A1 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | USP1, USP2, USP3 | NUDT1 3455/4885JAK1 159/4885EGLN2 2070/4885 |
| US-20150291593-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | PIK3C2B, PIK3C3, PIK3C2A | NUDT1 1982/4885JAK1 57/4885EGLN2 1239/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | NUDT1 1120/4885JAK1 69/4885EGLN2 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.